Samuel Jeyaraj  Daniel

Samuel Jeyaraj Daniel

Profile ID RP-000-4728 Joined 2023-01-21 2 articles
0Connections
10
Total Views
2
Total Publications
29
Publication Views

Articles(2)

Authors: Suganya Sekar, Samuel Daniel

DOI: 10.18231/j.ijced.2020.007

Volume6
Issue1
Pages25-29
Abstract

Introduction: Psoriasis is a disorder of chronic nature. But the present day systemic therapies for psoriasis of moderate to severe nature are associated with toxicity and also have a greater level of displeasure in the patients. Hence the current focus for treatment is with intermittent or combination therapy that helps to overcome the loss of effectiveness in treatment over time and decrease the side effects as a result of cumulative toxicities during monotherapy. Aim: To assess the effectiveness of oral Methotrexate and Etanercept combination therapy in comparison to Etanercept monotherapy for treatment of moderate to severe plaque type of psoriasis among patients. Materials and Methods: This was a prospective analytical study conducted in dermatology OPD of Madras Medical College, a tertiary care centre in south India between August 2015 and July 2016. About Forty subjects clinically diagnosed with plaque type of psoriasis based upon the clinical history and morphology of the dermatological lesions were included in this hospital based study depending on inclusion and exclusion criteria and were randomly allocated into two groups. Group C: Combination therapy with oral methotrexate and Etanercept and Group M:Monotherapy with Etanercept alone. All the patients were reviewed every 4 weeks at intervals of 0,4,8 and 12 weeks for complaints and for assessment of clinical response using PASI scoring and DLQI scoring and other investigations. Data was compiled and analyzed with the help of Statistical Package for Social Science (SPSS) Version 20.0. Results: Mean age of the study population was 37.43 10.1 years. Twenty two subjects were males (55%) and eighteen subjects were females (45%). The subjects who received Group C (Methotrexate and Etanercept combination therapy) therapy achieved 75% reduction of PASI in comparison to subjects who received Group M (Etanercept monotherapy) after 8 weeks (30% vs 5%) and after 12 weeks (100% vs 50%). Also Group C showed good response to treatment after 12 weeks in comparison to Group M (85% vs 50%) and this difference in proportion of treatment response between the two groups was statistically significant. Subjects who received Group C showed greater decline (77.4% vs 68.7) in DLQI score after 12 weeks in comparison to subjects who received Group M. Keywords: Combination therapy, Monotherapy, Etanercept, Methotrexate.

Authors: Rajalakshmi Ramamurthy, Samuel Jeyaraj Daniel

DOI: 10.18231/j.ijced.2019.071

Volume5
Issue4
Pages340-345
Abstract

Introduction: Scabies has been a major health problem in many countries worldwide because of its very high prevalence. The estimated prevalence varies from 0.2 to 71%. Nearly hundred million people are affected worldwide. Scabies remains a major problem in terms of its contagious nature and the secondary infections which occur as a result of the disease. Aims: To compare the efficacy of Topical Ivermectin and other scabicidal agents. To assess the improvement in severity of pruritus and severity of lesions. Materials and Methods: This was an prospective and comparative study conducted in dermatology OPD of Madras Medical College, a tertiary care centre in south India between Oct ’ 2015 and Aug’ 2016. About 90 clinically diagnosed Scabies cases were randomly segregated into three factions [Group G (GBHC) = 30 cases of scabies treated with 1% GBHC lotion, Group P (Permethrin) = 30 cases of scabies treated with 5% Permethrin cream and Group I (Ivermectin) = 30 cases of scabies treated with 0.5% Ivermectin cream. Patients response to treatment was followed up with severity of pruritus score and severity of lesions score at baseline, third and sixth week of treatment. Based on the assessment of these scores, the response to treatment was categorized into good, moderate and poor. Data was compiled and analyzed with the help of Statistical Package for Social Science (SPSS). Results: Mean age of the study population was 27.66 years. Forty seven subjects were males (52.2%) and forty three subjects were females (47.8%). In Group I (Ivermectin ) , 86.6%(26 out of 30 cases) had good response to treatment when compared to Group P (Permethrin) 36.7% (11 out of 30 cases) and Group G (GBHC) 10%(3 out of 30 cases). Group I (Ivermectin ) compared favorably to the other two drugs with nearly more than three fourth of the cases having significant improvement at an earlier stage while Group P (Permethrin) showed better response after twice application when compared to Group G (GBHC). Conclusions: From this study, it can be concluded that topical 0.5% Ivermectin can be considered as the first line of treatment modality for scabies among other available agents as it causes earlier and maximum therapeutic response. This study further emphasizes the need for newer effective drugs for treatment of scabies. Keywords: Scabies, Ivermectin, Permethrin, GBHC.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

No bio added yet.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Other Online Pages

Scholars in the same field

SD
Snehal dinesh borana
0 publications
HK
Dr Harnoor kaur
0 publications
BG
Bhupendra Gupta
0 publications
NA
Niyati Airan
Veer Chandra Singh Garhwali Government Institute of Medical Science and Research, Srinagar Garhwal, Uttarakhand.
0 publications
MR
Manjunath R Kudari
0 publications
VS
Vinny Sharma
0 publications
AD
Agrita Dhyani
Veer chandra singh garhwali government institute of medical science and research
0 publications
ST
Sahista Tarunum
0 publications
NB
Nirjan Biswas
0 publications
RM
RAVINDRA MOHAN
0 publications

Following

Nobody here yet.

Followers

Nobody here yet.

2 Publications